Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALXO 
Alx Oncology Holdings (ALXO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: ALXO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.25
1 Year Target Price $2.25
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.46% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.56M USD | Price to earnings Ratio - | 1Y Target Price 2.25 |
Price to earnings Ratio - | 1Y Target Price 2.25 | ||
Volume (30-day avg) 6 | Beta 1.16 | 52 Weeks Range 0.40 - 8.78 | Updated Date 07/12/2025 |
52 Weeks Range 0.40 - 8.78 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.16% | Return on Equity (TTM) -102.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -62073261 | Price to Sales(TTM) 5906.24 |
Enterprise Value -62073261 | Price to Sales(TTM) 5906.24 | ||
Enterprise Value to Revenue 4254.36 | Enterprise Value to EBITDA -2.35 | Shares Outstanding 53444000 | Shares Floating 31342780 |
Shares Outstanding 53444000 | Shares Floating 31342780 | ||
Percent Insiders 2.45 | Percent Institutions 79.75 |
Upturn AI SWOT
Alx Oncology Holdings
Company Overview
History and Background
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway. Founded in 2015, ALX Oncology's lead product candidate, evorpacept (ALX148), is a next-generation CD47 blocker designed to maximize efficacy and minimize the dose-limiting toxicities.
Core Business Areas
- Drug Development: Focuses on the discovery, development, and commercialization of therapies targeting the CD47 checkpoint pathway for cancer treatment. Their lead candidate, evorpacept (ALX148), is undergoing clinical trials for various cancer indications.
Leadership and Structure
Jaume Pons, Ph.D. is the President, Chief Executive Officer, and Chairman of the Board of ALX Oncology. The company has a typical organizational structure with departments focused on research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Evorpacept (ALX148): Evorpacept is a CD47 blocking fusion protein designed to enhance the activity of anti-cancer antibodies. Currently in clinical trials targeting various hematologic and solid malignancies. Market share data is not yet available due to its clinical stage. Competitors include Gilead Sciences (Magrolimab) and other companies developing CD47-targeting therapies.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing significant growth, driven by increasing cancer incidence and the development of novel therapies that harness the immune system to fight cancer. The CD47 checkpoint pathway is a promising area of research, with potential applications across a wide range of cancers.
Positioning
ALX Oncology is positioning itself as a leader in the CD47-targeting immuno-oncology space with its next-generation CD47 blocker, evorpacept. Their approach aims to improve efficacy and reduce toxicity compared to first-generation CD47 inhibitors.
Total Addressable Market (TAM)
The total addressable market for CD47-targeted therapies is estimated to be in the billions of dollars. ALX Oncology is positioned to capture a significant share of this market if evorpacept proves to be safe and effective in clinical trials.
Upturn SWOT Analysis
Strengths
- Novel approach to CD47 blockade (evorpacept)
- Experienced management team
- Strong intellectual property position
- Clinical-stage product candidate with promising early data
Weaknesses
- Reliance on a single lead product candidate
- High development costs and regulatory risks
- Competition from larger pharmaceutical companies
- No approved products generating revenue
Opportunities
- Positive clinical trial results for evorpacept
- Expansion into new cancer indications
- Partnerships with pharmaceutical companies
- Potential for breakthrough therapy designation
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other CD47 inhibitors
- Changes in the competitive landscape
Competitors and Market Share
Key Competitors
- GILD
- IMAB
- TGGTF
Competitive Landscape
ALX Oncology's key competitive advantage is its novel approach to CD47 blockade, which may offer improved efficacy and reduced toxicity compared to other CD47 inhibitors. However, the company faces competition from larger pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is related to the company's R&D spend.
Future Projections: Future growth is dependent on clinical trial results and regulatory approvals for evorpacept. Analyst data will be available closer to potential market approval
Recent Initiatives: Continued enrollment in ongoing clinical trials of evorpacept, exploration of new cancer indications, and continued research and development efforts
Summary
ALX Oncology is a clinical-stage company with a promising lead product candidate, evorpacept, targeting the CD47 checkpoint pathway. Its innovative approach could provide an edge in the competitive immuno-oncology landscape. The company faces the challenges of clinical development and competition from larger players. Positive clinical trial data will be crucial for its success, given the significant risks associated with biopharmaceutical development and reliance on a single pipeline product. Success relies on continued R&D spend and partnerships with pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- ALX Oncology Investor Relations
- SEC Filings (10K, 10Q)
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alx Oncology Holdings
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-07-17 | CEO & Director Mr. Jason W. Lettmann | ||
Sector Healthcare | Industry Biotechnology | Full time employees 65 | Website https://www.alxoncology.com |
Full time employees 65 | Website https://www.alxoncology.com | ||
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.